We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

137 hedge funds and large institutions have $643M invested in Intra-Cellular Therapies Inc. in 2017 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 43 increasing their positions, 23 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

370% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 10

87% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 23

67% more capital invested

Capital invested by funds: $385M → $643M (+$258M)

37% more funds holding

Funds holding: 100 → 137 (+37)

51% less call options, than puts

Call options by funds: $6.91M | Put options by funds: $14.2M

Holders
137
Holders Change
+37
Holders Change %
+37%
% of All Funds
3.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
47
Increased
43
Reduced
23
Closed
10
Calls
$6.91M
Puts
$14.2M
Net Calls
-$7.33M
Net Calls Change
-$12.6M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$21.3M
2
Millennium Management
Millennium Management
New York
+$20.3M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$14.5M
4
BI
BVF Inc
California
+$13.9M
5
PA
Perceptive Advisors
New York
+$13.6M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$19.5M
2
BlackRock
BlackRock
New York
-$7.95M
3
Goldman Sachs
Goldman Sachs
New York
-$5.18M
4
State Street
State Street
Massachusetts
-$3.91M
5
GTC
Ghost Tree Capital
New York
-$2.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$5.32M +$743K +50,659 +18%
HI
27
HBK Investments
Texas
$4.73M +$4.4M +300,000 New
Norges Bank
28
Norges Bank
Norway
$4.4M +$1.61M +110,000 +65%
Point72 Asset Management
29
Point72 Asset Management
Connecticut
$4.11M +$3.83M +260,700 New
CWG
30
C WorldWide Group
Denmark
$3.82M +$355K +24,194 +11%
Goldman Sachs
31
Goldman Sachs
New York
$3.59M -$5.18M -353,146 -61%
DekaBank Deutsche Girozentrale
32
DekaBank Deutsche Girozentrale
Germany
$3.35M – – –
MIM
33
Monashee Investment Management
Massachusetts
$3.06M – – –
RSCM
34
Rock Springs Capital Management
Maryland
$2.96M – – –
FMBTD
35
First Midwest Bank Trust Division
Illinois
$2.92M +$418K +28,487 +18%
CS
36
Candriam SCA
Luxembourg
$2.79M +$323K +22,000 +14%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$2.67M -$31.1K -2,121 -1%
CCI
38
Columbus Circle Investors
$2.48M +$2.31M +157,305 New
Federated Hermes
39
Federated Hermes
Pennsylvania
$2.46M -$402K -27,416 -15%
ARTA
40
A.R.T. Advisors
New York
$2.23M +$1.31M +89,464 +173%
Balyasny Asset Management
41
Balyasny Asset Management
Illinois
$2.2M +$2.04M +139,353 New
Charles Schwab
42
Charles Schwab
California
$2.1M -$16.2K -1,102 -0.8%
SSA
43
Schonfeld Strategic Advisors
New York
$2.08M +$1.94M +131,980 New
DM
44
Deerfield Management
New York
$1.86M +$1.73M +118,116 New
SFM
45
Soros Fund Management
New York
$1.8M +$1.67M +114,000 New
JGC
46
J. Goldman & Co
New York
$1.75M +$392K +26,700 +32%
TCIM
47
TIAA CREF Investment Management
New York
$1.71M -$40.6K -2,769 -2%
WMSA
48
Weiss Multi-Strategy Advisers
New York
$1.65M -$166K -11,300 -10%
PAM
49
Panagora Asset Management
Massachusetts
$1.56M +$1.45M +99,024 New
Parallax Volatility Advisers
50
Parallax Volatility Advisers
California
$1.55M +$1.44M +98,088 New
1
2
3 4 5

ITCI Hedge Fund Activity: Q3 2017 in Review

137 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2017, worth a combined $643M — up 67% from $385M a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new ITCI positions and 10 closed out — a net gain of 37 holders — while 43 added to existing stakes and 23 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $21.3M. The largest seller was Citadel Advisors, cutting an estimated $19.5M.

  • 137 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2017, up from 100 in Q2 2017.
  • Funds reported $643M of Intra-Cellular Therapies Inc. stock for Q3 2017, up 67% quarter-over-quarter.
  • 47 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2017 and 10 closed out, a net change of +37 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q3 2017 was Fidelity Investments, an estimated $21.3M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q3 2017 was Citadel Advisors, an estimated $19.5M sold.

Based on aggregated 13F filings for Q3 2017.